NICE National Institute for Health and Care Excellence

NICE guidance

Bevacizumab for treating relapsed, platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer (terminated appraisal)

Technology appraisal guidance
Published: 26 August 2015
nice.org.uk/guidance/ta353

Contents

Advice

NICE is unable to make a recommendation about the use in the NHS of bevacizumab for treating relapsed, platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer because no evidence submission was received from Roche Products for the technology.

Background

Roche Products was invited to submit evidence for this single technology appraisal for bevacizumab in March 2015.

Roche conceded that it would not be possible to demonstrate the cost effectiveness of bevacizumab for relapsed, platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer. Bevacizumab cannot be given special consideration as a treatment used at the end of life because the total population eligible for treatment across all its licensed indications is too large.

NICE has therefore terminated this single technology appraisal.

Information

NHS organisations should take into account the reasons why the company did not make an evidence submission when considering whether or not to recommend local use of bevacizumab for relapsed, platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer. If, after doing this, organisations still wish to consider bevacizumab for relapsed, platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer, they should follow the advice on rational local decision-making in the NHS Constitution for England and the NHS Commissioning Board and Clinical Commissioning Groups (Responsibilities and Standing Rules) Regulations 2012, which outlines the approach that should be adopted in circumstances in which NICE guidance is unavailable.

NICE will review the position at any point if the company indicates that it wishes to make a full submission.

ISBN: 978-1-4731-1401-2

Accreditation